House Democrats on Wednesday introduced a bill to allow Medicare to negotiate drug prices, hoping to lay the groundwork for a push on the issue next year.
President TrumpDonald TrumpGrant Woods, longtime friend of McCain and former Arizona AG, dies at 67 Super PACs release ad campaign hitting Vance over past comments on Trump Glasgow summit raises stakes for Biden deal MORE previously supported the idea, which is usually associated with Democrats, but did not propose it as part of the drug pricing plan he released in May.
Democrats have attacked Trump for not going far enough to reduce soaring medication costs.
“This bill calls the President's bluff on his drug pricing promises,” said Rep. Lloyd DoggettLloyd Alton DoggettCities become pawns in redistricting game LIVE COVERAGE: Tax hikes take center stage in Ways and Means markup American workers need us to get this pandemic under control around the world MORE (D-Texas), who is a lead sponsor of the bill along with Reps. Peter WelchPeter Francis WelchDemocrats weigh changes to drug pricing measure to win over moderates Schumer feels heat to get Manchin and Sinema on board Failed drug vote points to bigger challenges for Democrats MORE (D-Vt.) and Elijah CummingsElijah Eugene CummingsFormer GOP congressional candidate Kimberly Klacik suing Candace Owens for defamation Former Cummings staffer unveils congressional bid McCarthy, GOP face a delicate dance on Jan. 6 committee MORE (D-Md.).
Doggett said in an interview that lawmakers are introducing the bill now so that it can be fine-tuned and ready for a push next year if Democrats win back the House in November.
The measure has over 60 Democratic cosponsors.
The Trump administration has taken several steps on drug pricing already this year. Last week, for example, officials announced they are exploring allowing importation of drugs to increase competition when there are price spikes on old, off-patent drugs, a potentially significant step.
But Democrats want to go farther, and use Medicare’s negotiating power to bring down costs.
"It defies logic that the federal government is not using its enormous purchasing power to get a better deal for seniors on prescription drugs,” Welch said.